2015
DOI: 10.1177/0272989x15598528
|View full text |Cite
|
Sign up to set email alerts
|

HIV Treatment and Prevention

Abstract: Objective. To create a simple model to help public health decision makers determine how to best invest limited resources in HIV treatment scale-up and prevention. Method. A linear model was developed for determining the optimal mix of investment in HIV treatment and prevention, given a fixed budget. The model incorporates estimates of secondary health benefits accruing from HIV treatment and prevention and allows for diseconomies of scale in program costs and subadditive benefits from concurrent program implem… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
23
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 23 publications
(23 citation statements)
references
References 54 publications
0
23
0
Order By: Relevance
“…31 , 32 It adds to a growing body of literature on resource allocation for HIV prevention, which highlights the need to account for local epidemiology to maximise the efficiency of HIV prevention planning. 6 , 33 , 34 , 35 , 36 , 37 …”
Section: Discussionmentioning
confidence: 99%
“…31 , 32 It adds to a growing body of literature on resource allocation for HIV prevention, which highlights the need to account for local epidemiology to maximise the efficiency of HIV prevention planning. 6 , 33 , 34 , 35 , 36 , 37 …”
Section: Discussionmentioning
confidence: 99%
“…While the use of mathematical optimization techniques to allocate limited HIV resources is not new in the field of health economics [11,8,13,12,4], our approach is unique in emphasizing the capacity of the fixed epidemic assumption (when appropriate) to allow for flexible and robust allocation analyses.…”
Section: Introductionmentioning
confidence: 99%
“…In general, the (incremental) net monetary benefit of an intervention is linear in parameters with a one-time effect (e.g., the prevalence of a disease at one point in time or the outcome of a one-time screening test). When an effect accrues over time, such as for a reduction in the annual transition rate of a disease complication or death, linearity is often used as an approximation (see, e.g., [ 8 ]). At each time, the policy-maker can choose to invest in the medical intervention and/or to purchase sample information about the uncertain dynamic parameter.…”
Section: Introductionmentioning
confidence: 99%